Advanced Fertility Center of Chicago. Utility of Perioperative Measurement of Cell-Free DNA and Circulating Tumor DNA in Informing the Prognosis of GI Cancers: A Systematic Review. MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma. Smita S. Joshi, Steven Brad Maron, Daniel V.T. This work was supported by a National Institutes of Health K12 award (CA139160-01A), University of Chicago Comprehensive Cancer Center Award in Precision Oncology, and LLK Foundation Award (Dr Catenacci). Learn about what makes them similar and what sets them apart. Catenacci DVT, Tang R, Oliner K, Ang A, Loberg RD, OE, Xu P, Henderson L, Ruzzo A, Graziano F. Comprehensive genomic profiling of biliary tract cancers to reveal tumor-specific differences and frequency of clinically relevant genomic alterations. Final Analysis of a phase IB/Randomized phase II study of Gemcitabine (G) plus Placebo (P) or Vismodegib (V), a Hedgehog (Hh) pathway inhibitor, in patients (pts) with metastatic pancreatic cancer (PC): A University of Chicago Phase II Consortium study. Catenacci, Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study, Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed Al-Rajabi, Andrew Scott Paulson, Mitesh J. Borad, David Gallinson, Adrian Murphy, Do Youn Oh, Efrat Dotan, Daniel V.T. U.S. District Judge Jorge L. Alonso ordered Dr. Daniel V.T. Cancer surgeons, or surgical oncologists, remove tumors, while medical oncologists treat cancers with chemotherapy. Catenacci, Eric Van Cutsem, Tao Ji, Christine F. Lihou, Hui-Ling Zhen, Luis Fliz, Arndt Vogel, The Chicago Consensus on peritoneal surface malignancies: Management of neuroendocrine tumors, Darryl Schuitevoerder, Alejandro Plana, Francisco J. Izquierdo, Laura A. Lambert, Xavier M. Keutgen, Jeremiah L. Deneve, Steven A. Ahrendt, Mazin AlKasspooles, Farin Amersi, Wilbur B. Bowne, Charles Komen Brown, Andrea Hayes-Jordan, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Lindsay Alpert, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. NPI Lookup NPI Database. Dr. Daniel V. Catenacci is an oncologist in Chicago, Illinois and is affiliated with University of Chicago Medical Center.He received his medical degree from Wayne State University School of . Schedule your appointment online for primary care and many specialties. Catenacci is accused of buying 8,743 shares of Five Prime Therapeutics, the company sponsoring the clinical trial, the day before results were released to the public. Call or Book Online. A safety and Feasibility trial. AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dualagent dose finding trials, Jiaying Lyu, Yuan Ji, Naiqing Zhao, Daniel V.T. Dr. Daniel Catenacci, the head of an oncology program at the University of Chicago, was hit with federal charges Monday, accused of insider trading. Catenacci, Mitesh J. Borad, John Bridgewater, William P. Harris, Adrian Murphy, Do Youn Oh, Jonathan R. Whisenant, Maeve A. Lowery, Lipika Goyal, Rachna T. Shroff, Anthony B. El-Khoueiry, Bin Fan, Bin Wu, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi Sumant Pandya, Juan W. Valle, Andrew X. Zhu, The Chicago Consensus on peritoneal surface malignancies: Management of desmoplastic small round cell tumor, breast, and gastrointestinal stromal tumors, Francisco J. Izquierdo, Alejandro Plana, Darryl Schuitevoerder, Andrea Hayes-Jordan, Jeremiah L. Deneve, Mazin AlKasspooles, Wilbur B. Bowne, Charles Komen Brown, John M. Kane, Kaitlyn J. Kelly, Timothy J. Kennedy, Ugwuji N. Maduekwe, Grace Z. Mak, Marcovalerio Melis, Richard E. Royal, Daniel E. Abbott, Sherif Abdel-Misih, Farin Amersi, Amanda K. Arrington, Brian D. Badgwell, Robert M. Barone, Joel M. Baumgartner, Richard N. Berri, Lana Bijelic, Dan G. Blazer, Daniel V.T. Washington D.C., Dec. 20, 2021 . . He attended medical school at Wayne State University in Detroit. Cohen DJ, Christos PJ, Catenacci DVT, Kindler HL, Bekaii-Saab TB, Tahiri S, Janjigian YY, Gibson MK, Chan E, Rajdev L, Urba S, Wade JL, Kozuch P, Love E, Vandris K, Takebe N, Hochster HS, Sparano JA, A randomized pilot phase I study of modified Carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine (CEA-vac) in patients (pts) with pancreatic adenocarcinoma (PC), Geynisman DM, Zha Y, Kunnavakkam R, Aklilu D, Catenacci DVT, Polite BN, Rosenbaum A, Namakydoust A, Karrison T, Gajewski TF, Kindler HL. Catenacci, Stephanie Moya, Samantha Lomnicki, Leah Chase, Bryan Peterson, Natalie Reizine, Lindsay Alpert, Namrata Setia, Shu-Yuan Xiao, John Hart, Uzma D. Siddiqui, D. Kyle Hogarth, Oliver S. Eng, Kiran K. Turaga, Kevin K. Roggin, Mitchell C. Posner, Paul J. Chang, Sunil Narula, Murtuza Rampurwala, Yuan Ji, Theodore Karrison, Chih-Yi Liao, Blase N. Polite, Hedy L. Kindler, Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy, Yaniv Berger, Mihai Giurcanu, Charles C. Vining, Darryl Schuitevoerder, Mitchell C. Posner, Kevin K. Roggin, Blase N. Polite, Chih-Yi Liao, Oliver S. Eng, Daniel V.T. ACR Appropriateness Criteria Staging and Follow-Up of Esophageal Cancer. Moderated Roundtable Discussion: Defining the major knowledge gaps and priorities for future research of cholangiocarcinoma. Daniel V.T. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience. Dr. Daniel Vt Catenacci, MD, is a Hematology/Oncology specialist in Chicago, Illinois. Catenacci, Daniel D. Von Hoff, Carlos Becerra, Nancy Whiting, Jing Yang, Brian M. Wolpin, A Phase I Study of FOLFIRINOX Plus IPI-926, a Hedgehog Pathway Inhibitor, for Advanced Pancreatic Adenocarcinoma, Andrew H. Ko, Noelle K. LoConte, Margaret A. Tempero, Evan J. Walker, R. Kate Kelley, Stephanie Lewis, Wei-Chou Chang, Emily Kantoff, Michael W. Vannier, Daniel V.T. Gastroesophageal cancer: focus on epidemiology, classification, and staging. A spokesman for the University of Chicago said Catenacci is on a leave of absence and not currently engaged in research or otherwise seeing patients. A subgroup cluster-based Bayesian adaptive design for precision medicine. Hembrough T, Liao WL, Henderson L, Xu P, Burrows J, Catenacci DVT. Gastroesophageal Adenocarcinoma in The Era of Targeted Therapies: A Focus on MET. adenocarcinoma (GEC). Dr. Daniel Catenacci, MD is a Medical Oncology Specialist in Chicago, IL. (608) 265-1700. Catenacci, Vincent A. Miller, Chaitanya Churi, Siraj M. Ali, Philip J. Stephens. J E Berchuck, F Facchinetti, D F DiToro, I Baiev, U Majeed, S Reyes, C Chen, K Zhang, R Sharman, P L S Uson Junior, J Maurer, R T Shroff, C C Pritchard, M-J Wu, D V T Catenacci, M Javle, L Friboulet, A Hollebecque, N Bardeesy, A X Zhu, J K Lennerz, B Tan, M Borad, A R Parikh, L A Kiedrowski, R K Kelley, K Mody, D Juric, L Goyal. Dr. Michelle Catenacci, MD is a Reproductive Endocrinology & Infertility Specialist in Gurnee, IL and has over 18 years of experience in the medical field. Cholangiocarcinoma and #2 Rectal Cancer, and Discussion. Meeting Highlights: Gastrointestinal Cancer.. Through this position, Catenacci allegedly received confidential information about the company and its clinical trial results. Chih-Yi (Andy) Liao, MD MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma. Catenacci, Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study, Yung Jue Bang, Yoon-Koo Kang, Daniel V.T. Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study. Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Following this, Dr Catenacci held positions at . Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Radiation oncologists use multiple forms of radiation in an effort to eliminate tumors. Catenacci, Carlos H. F. Chan, Clifford S. Cho, M. Haroon A. Choudry, Callisia N. Clarke, James C. Cusack, Abraham H. Dachman, Sean P. Dineen, Oliver S. Eng, Leopoldo J. Fernandez, James Fleshman, T. Clark Gamblin, Alexandra Gangi, Georgios V. Georgakis, Erin W. Gilbert, Martin D. Goodman, Anand Govindarajan, Travis E. Grotz, Vadim Gushchin, Nader Hanna, Carla Harmath, Aliya N. Husain, Kamran Idrees, Chukwuemeka Ihemelandu, Haejin In, David Jiang, Fabian M. Johnston, Giorgos C. Karakousis, Hedy L. Kindler, Michael D. Kluger, Byrne Lee, Chih-Yi Liao, Lloyd A. Mack, Joshua M. V. Mammen, Melvy Sarah Mathew, Nelya Melnitchouk, Ryan P. Merkow, Harveshp Mogal, Mecker G. Mller, Aytekin Oto, Colette R. Pameijer, Sam G. Pappas, Patricio M. Polanco, Blase N. Polite, Sanjay S. Reddy, George I. Salti, Armando Sardi, Maheswari Senthil, Namrata Setia, Scott K. Sherman, Lucas Sideris, Joseph Skitzki, Sandy Tun, Jula Veerapong, Konstantinos I. Votanopoulos, Michael G. White, Joshua H. Winer, Shu-Yuan Xiao, Rhonda K. Yantiss, Nita Ahuja, Andrew M. Lowy, H. Richard Alexander, Jesus Esquivel, Jason M. Foster, Daniel M. Labow, Edward A. Levine, Charles A. Staley, Paul H. Sugarbaker, David L. Bartlett, Kiran K. Turaga, First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors, Gerald Steven Falchook, Razelle Kurzrock, Hesham M. Amin, Wenyuan Xiong, Siqing Fu, Sarina Anne Piha-Paul, Filip Janku, Ghazaleh Eskandari, Daniel V.T. Daniel V.T. Catenacci, Shiwei Duan, Mark J. Ratain. Tumor Board: Management of Challenging Cases of Upper Gastrointestinal Cancers (ARS)" (Invited Panelist), Tumors to the Liver: Metastatic Adenocarcinoma of Unknown Origin Work up before Therapy and Role of Molecular Profiling to Sort it out, Does Molecular Profiling Predict Response to Therapy?, "Tumor Genomics, Immunotherapy, Clinical Trials, and Other Hopes for the Future. (Committee Chair and Organizer, Moderator, Speaker). A pilot randomized phase I study of modified Carcinoembryonic antigen (CEA) peptide (CAP1-6D)/Montanide/GM-CSF-vaccine (CEA-vac) in patients KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined antiRAS/RAF/MEK/ERK Dr Catenacci is board certified in medical oncology. Catenacci, Sarit Schwartz, Shankar Sellappan, Yuan Tian, Rosalba Miceli, Alessandro Pellegrinelli, Elisa Giommoni, Enrico Aitini, Francesca Spada, Gerardo Rosati, Alberto Marchet, Francesca Pucci, Alberto Zaniboni, Stefano Tamberi, Tiziana Pressiani, Gianni Sanna, Maurizio Cantore, Stefania Mosconi, Paola Bolzoni, Carmine Pinto, Lorenza Landi, Hector Soto Parra, Luigi Cavanna, Salvatore Corallo, Antonia Martinetti, Todd Hembrough, Filippo Pietrantonio. MD, in the Section of Gastroenterology at the University of Chicago. Catenacci, Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma, Eirini Pectasides, Matthew D. Stachler, Sarah Derks, Yang Liu, Steven Brad Maron, Mirazul Islam, Lindsay Alpert, Heewon A. Kwak, Hedy L. Kindler, Blase N. Polite, Manish R. Sharma, Kenisha Allen, Emily O'Day, Samantha Lomnicki, Melissa Maranto, Rajani Kanteti, Carrie Fitzpatrick, Christopher R. Weber, Namrata Setia, Shu-Yuan Xiao, John Hart, Rebecca J. Nagy, Kyoung-Mee Kim, Min-Gew Choi, Byung-Hoon Min, Katie S. Nason, Lea O'Keefe, Masayuki Watanabe, Hideo Baba, Rick Lanman, Agoston T. Agoston, David J. Oh, Andrew Dunford, Aaron R. Thorner, Matthew D. Ducar, Bruce M. Wollison, Haley A. Coleman, Yuan Ji, Mitchell C. Posner, Kevin K. Roggin, Kiran K. Turaga, Paul J. Chang, Kyle Hogarth, Uzma D. Siddiqui, Andres Gelrud, Gavin Ha, Samuel S. Freeman, Justin Rhoades, Sarah C. Reed, Greg Gydush, Denisse Rotem, Jon M. Davison, Yu Imamura, Viktor A. Adalsteinsson, Jeeyun Lee, Adam J. Bass, Daniel V.T. UW Carbone Cancer Center Medical Oncology Clinic. DANIEL CATENACCI, 207R00000X - Internal Medicine Doctors & Physicians in CHICAGO, IL. . Gain a better understanding of fertility as we explore what happens during ovulation and how to get pregnant. Catenacci, Agnes Ang, Wei-Li Liao, Jing Shen, Emily O'Day, Robert D. Loberg, Fabiola Cecchi, Todd Hembrough, Annamaria Ruzzo, Francesco Graziano, A Phase II Randomized Trial (GO27827) of FirstLine FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer, Johanna C. Bendell, Howard S. Hochster, Lowell L. Hart, Irfan Firdaus, Joseph R. Mace, Joshua J. McFarlane, Mark Kozloff, Daniel V.T. Catenacci DVT, Bahary N, Horiba N, Nattam S, Marsh R, Wallace J, Rajdev L, Sleckman B, Cohen D, Lenz HJ, Stiff P, Thomas S, Xu P, Henderson L, Vannier M, Karrison T, Stadler WM, Kindler HL. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. Catenacci, Steven Brad Maron, Kiran K. Turaga. Catenacci, Alan P. Venook, Hedy L. Kindler. Open for more information, Community Physician Learn more about pregnancy after a miscarriage as we discuss what you need to know about your body and how to prepare for a future pregnancy. Catenacci, Marwan Fakih, Catalin Barbacioru, Jing Zhao, Marcin Sikora, Stephen R. Fairclough, Hyuk Lee, Kyoung-Mee Kim, Seung Tae Kim, Jinchul Kim, Danielle Gavino, M. Benavides, Nir Peled, Timmy Nguyen, Mike Cusnir, Ramez N. Eskander, Georges Azzi, Takayuki Yoshino, Kimberly C. Banks, Victoria M. Raymond, Richard B. Lanman, Darya Chudova, Amir Ali Talasaz, Scott Kopetz, Jeeyun Lee, Justin I. Odegaard. Through his role at . Bemarituzumab with modified FOLFOX6 for advanced FGFR2-positive gastroesophageal cancer: FIGHT Phase III study design. Five Cancer Therapies to Get Excited About in 2023. 2023 The University of Chicago Medical Center. Quantification of MET expression using Mass Spectrometry (MS): Assay Precision and Stability in FFPE Tumor Tissue. The authors thank L. Jeffrey Medeiros, MD, for critical review of this manuscript. Telehealth services available. Catenacci, Angel N. Desai, Ishani Ganguli, Sebastien Haneuse, Sharon K. Inouye, Elizabeth A. Jacobs, Kristin Kan, Howard S. Kim, Arden M. Morris, Olugbenga Ogedegbe, Eli N. Perencevich, Roy H. Perlis, Elizabeth C. Powell, Gordon D. Rubenfeld, Lawrence N. Shulman, N. Seth Trueger, Stephan D. Fihn. Pembro + CROSS in GEJ from Dr. Harry Yoon, @GIcancerDoc, @the_danielahn and team in @CCR_AACR. Catenacci, A phase 1 clinical trial of ASG-5ME, a novel drug-antibody conjugate targeting SLC44A4, in patients with advanced pancreatic and gastric cancers, Andrew L. Coveler, Andrew H. Ko, Daniel V.T. Daniel M. Geynisman, Daniel V.T. . Schrock, A. B.,Ouyang, C.,Sandhu, J.,Sokol, E.,Jin, D.,Ross, J. S.,Miller, V. A.,Lim, D.,Amanam, I.,Chao, J.,Catenacci, D.,Cho, M.,Braiteh, F.,Klempner, S. J.,Ali, S. M.,Fakih, M. Phase I Study of AMG 337, a Highly Selective Small-molecule MET Inhibitor, in Patients with Advanced Solid Tumors. Catenacci, Sandra McGuigan, Lukas Makris, Toshihiko Doi, Kohei Shitara. He attended and graduated from Wayne State University School Of Medicine in 2003, having over 19 years of diverse experience, especially in Hematology/Oncology. To settle the SEC's civil charges, Catenacci has agreed to pay a penalty in an amount to be determined by the court at a later date, the SEC said. Personalized Colon Cancer Care: Are we there yet?. Dr. Daniel Catenacci, MD is a oncology specialist in Chicago, IL. Dr Daniel Catenacci - University of Chicago, Chicago, USA. Pancreatic Cancer: Hedgehog Signaling & the new era of FOLFIRINOX. Josep Tabernero, K. Shitara, Aziz Zaanan, Toshihiko Doi, Sylvie Lorenzen, E. Van Cutsem, Lorenzo Fornaro, Daniel V.T. Catenacci DVT, Faoro L, Loganathan S, Zumba O, Kindler HL, Salgia R. Phosphorylated Met Is Preferrentially Located in the Nucleus of Hepatoblastomas. Comprehensive Genomic Profiling Of Biliary Tract Cancers Reveals Tumor Specific Differences and a High Frequency of Clinically Relevant Genomic Alterations. Ross JS, Wang K, Javle MM, Catenacci DVT, Shroff RT, Ali SM, Elvin JA, Chmielecki J, Yelensky R, Lipson D, Miller VA, Stephens PJ, Meric-Bernstam. He is affiliated with many hospitals including The University Of Chicago Medical Center. Exploring New Approaches for Locally Advanced Gastroesophageal Adenocarcinomas: TNT, Irinotecan, and ctDNA. Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management? Dr. Schell is board certified in Obstetrics and Gynecology, with a sub-specialty board certification in Reproductive Endocrinology and Infertility. According to the charges, Catenacci served as one of the lead physicians and primary field investigators on a clinical trial by a California-based biotechnology company, identified only as Company A. Andrew X. Zhu, Teresa Macarulla, Milind Javle, R. Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V.T. 600 Highland Ave. / Madison, WI. A pan-cancer organoid platform for precision medicine. Catenacci is an associate professor of medicine, according to his LinkedIn profile and biography on the University of Chicago's website. Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results. Find other locations and directions. Catenacci, Harry H. Yoon, Erluo Chen, David Adelberg, Chie-Schin Shih, Sukrut Shah, Pooja Bhagia, Zev A. Wainberg. Both bring a successful background in biotech and not only discuss . Dr. Catenacci's office is located at Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel. Elena Elimova, Yelena Y. Janjigian, Mary F. Mulcahy, Daniel V.T. Catenacci DVT, Henderson L, Xu P, Burrows J, Hembrough T, Catenacci DVT, Polite B, Henderson L, Xu P, Carey GB, Rambo B, Liao WL, Hembrough T, Burrows J, Zhao L, Hart J, Xiao SY, Karrison T, Kindler HL, Towards personalized treatment for gastroesophageal adenocarcinoma: strategies to address inter- and intra- patient tumor heterogeneity: PANGEA. Robert de Wilton Marsh, Mark S. Talamonti, Marshall S. Baker, Mitchell C. Posner, Kevin K. Roggin, Jeffrey B. Matthews, Daniel V.T. He previously received a K23 career development award from the National Cancer Institute. Catenacci is an associate professor of medicine and oncologist, according to his LinkedIn profile and biography on the University of Chicago's Web site. Exploratory PD-L1 expression on extracellular vesicles is interesting. E An, C-Y Ock, T-Y Kim, K-H Lee, S-W Han, S-A Im, T-Y Kim, W-L Liao, F Cecchi, A Blackler, S Thyparambil, W H Kim, J Burrows, T Hembrough, D V T Catenacci, D-Y Oh, Y-J Bang. Dr. Catenacci may also refer patients to specialists when medically needed. Plan for medical costs now so unexpected expenses don't derail your retirement. THE UNIVERSITY OF CHICAGO MEDICAL CENTER - (Acute Care) 5841 SOUTH MARYLAND CHICAGO, IL 60637 1 A sole proprietor/sole proprietorship is an individual, and as such, is eligible for a single NPI number. Tomasz Oliwa, Steven Brad Maron, Leah Chase, Samantha Lomnicki, Daniel V.T.

Santa Barbara Mugshots, Black Coffee Your Eyes, Mike Trout High School Gpa,